Skip to main content

mat2a inhibitor bg-89894

Generic: MAT2A Inhibitor BG-89894

mat2a inhibitor bg-89894: 2 clinical trials tracked.

mat2a inhibitor bg-89894 evidence translation

What we can confirm

2 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about mat2a inhibitor bg-89894, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 1 study sponsors

Related indications

Advanced Solid Tumor
Clinical Trial Registry Records (2)

A Phase 1a/b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of PRMT5 Inhibitor BGB-58067 Alone and in Combination With Anticancer Agents in Patients With Advanced Solid Tumors

NCT06589596Registry updated 2026-09-14·Phase 1·ONC
Recruiting

Primary endpoint: Phase 1a: Number of Participants with Adverse Events and Serious Adverse Events

Interventionalopen525 targetStarted 2025-01Completion 2027-0950 sites · Australia, Brazil, China, United StatesBeOne Medicines

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-89894 (SYH2039) Tablets in Patients With Advanced Solid Tumors

NCT06568614Registry updated 2026-05-12·Phase 1·ONC
Terminated

Primary endpoint: Phase 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

Interventionalopen29 targetStarted 2024-10Completion 2026-0420 sites · Australia, China, United StatesBeOne Medicines